Saturday, November 12, 2022 10:44:32 AM
HappyLibrarian,
I actually agree!; ). This is about Dr. Linda Liau NOT NWBO or it’s investors. This is as it should be. MANUFACTURING is about NWBO and it’s partners. Once Dr. Linda Liau gets the spotlight THEN the rest will follow. Linda Powers would never front run Dr. Linda Liau if at all possible and Dr. Linda Liau prefers to be outside of the limelight and acknowledge others before accepting accolades for her part in any effort. She fought to be chair at UCLA because it was the right thing to do not just for herself but for women in a field historically dominated by men and where women’s contributions were not acknowledged to the fullest extent deserved. As a matter of fact, it was another woman,Linda Powers, who was not only willing, like Anton Boynton, but able to move DCVax forward to a completed Phase 3 trial. That was something that Anton Boynton did not have the capacity to do as evidenced by very near bankruptcy of NWBO before Linda Powers took over and rescued it.
So... right now it’s all about Dr. Linda Liau as it should be. Will the following week be a different story?; ). Best wishes.
I actually agree!; ). This is about Dr. Linda Liau NOT NWBO or it’s investors. This is as it should be. MANUFACTURING is about NWBO and it’s partners. Once Dr. Linda Liau gets the spotlight THEN the rest will follow. Linda Powers would never front run Dr. Linda Liau if at all possible and Dr. Linda Liau prefers to be outside of the limelight and acknowledge others before accepting accolades for her part in any effort. She fought to be chair at UCLA because it was the right thing to do not just for herself but for women in a field historically dominated by men and where women’s contributions were not acknowledged to the fullest extent deserved. As a matter of fact, it was another woman,Linda Powers, who was not only willing, like Anton Boynton, but able to move DCVax forward to a completed Phase 3 trial. That was something that Anton Boynton did not have the capacity to do as evidenced by very near bankruptcy of NWBO before Linda Powers took over and rescued it.
So... right now it’s all about Dr. Linda Liau as it should be. Will the following week be a different story?; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
